- patients with known immunoglobulin a deficiency (high risk of severe or fatal anaphylactic reactions) - patients who are on a ventilator - patients with past history of severe transfusion reaction including transfusion-related acute lung injury (trali) or anaphylaxis - patients with a baseline requirement for supplemental oxygen due to chronic lung disease or with known history of either moderate-to-severe asthma or emphysema. - female subjects who report that they are pregnant or breastfeeding - receipt of pooled immunoglobulin in the past 30 days - patients must be willing to not take any another alternative experimental treatment for covid-19 from the time they undergo enrollment until the 28-day follow-up phone call •. participants who are being treated with remdesivir and have had their first dose of remdesivir greater than 24 hours prior to the time they will receive their first dose of convalescent plasma - patients with severe disease due to covid-19, as manifested by a need for vasopressors, and/or diagnosis of acute respiratory distress syndrome

- patients with known immunoglobulin a deficiency (high risk of severe or fatal anaphylactic reactions) - patients who are on a ventilator - patients with past history of severe transfusion reaction including transfusion-related acute lung injury (trali) or anaphylaxis - patients with a baseline requirement for supplemental oxygen due to chronic lung disease or with known history of either moderate-to-severe asthma or emphysema. - female subjects who report that they are pregnant or breastfeeding - receipt of pooled immunoglobulin in the past 30 days - patients must be willing to not take any another alternative experimental treatment for covid-19 from the time they undergo enrollment until the 28-day follow-up phone call •. participants who are being treated with remdesivir and have had their first dose of remdesivir greater than 24 hours prior to the time they will receive their first dose of convalescent plasma - patients with severe disease due to covid-19, as manifested by a need for vasopressors, and/or diagnosis of acute respiratory distress syndrome